BioAtla Inc. Common Stock (BCAB)
Stock · NASDAQ · Health Care
$1.36as of 10/16/2026
Price chart
Active signals
BCAB Signal Track Record
How signals performed across all stocks →What BCAB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | -8.3% | 42% | September 16, 2026 |
| Bollinger Band Breakdown | 26 | -3.8% | 46% | August 28, 2026 |
| Bollinger Band Breakout | 18 | +2.1% | 50% | June 30, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -0.3% | 50% | October 4, 2024 |
| Any 20-session window (baseline) | -6.7% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BCAB
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedot…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 41
- Website
- www.bioatla.com/
Fundamentals
- 1-day range
- Market cap
- $5.53M
- P/E (trailing)
- —
- P/E (forward)
- -0.97
- EPS (trailing)
- $-25.56
- Dividend yield
- —
- Beta
- 0.62
- Avg. volume
- 57.5K
BioAtla Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BCABBioAtla Inc. Common Stock$1.36▲ 4.62%Market cap $5.53MP/E —$1.07$71.5
- VIVSVivoSim Labs Inc. Common Stock$0.16▼ 5.88%Market cap $5.53MP/E —$0.1495$3.4
- PMCBPharmaCyte Biotech Inc. Common Stock$0.3402▼ 4.81%Market cap $6.34MP/E —$0.3339$1.51
- LIMNLiminatus Pharma Inc. Class A Common Stock$3.04▼ 5.30%Market cap $6.64MP/E —$3.25$141.5
- CLDICalidi Biotherapeutics Inc. Common Stock$0.837▼ 3.79%Market cap $4.38MP/E —$0.82$27.84
- AIMAIM ImmunoTech Inc. Common Stock$0.17▲ 0.00%Market cap $7.51MP/E —$0.1605$2.79
- CELZCreative Medical Technology Holdings Inc. Common Stock$0.741▼ 9.39%Market cap $7.58MP/E —$0.62$6.25
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BCAB BioAtla Inc. Common Stock | $5.53M | — | $1.36 | ▲ 4.62% | $1.07$71.5 |
| VIVS VivoSim Labs Inc. Common Stock | $5.53M | — | $0.16 | ▼ 5.88% | $0.1495$3.4 |
| PMCB PharmaCyte Biotech Inc. Common Stock | $6.34M | — | $0.3402 | ▼ 4.81% | $0.3339$1.51 |
| LIMN Liminatus Pharma Inc. Class A Common Stock | $6.64M | — | $3.04 | ▼ 5.30% | $3.25$141.5 |
| CLDI Calidi Biotherapeutics Inc. Common Stock | $4.38M | — | $0.837 | ▼ 3.79% | $0.82$27.84 |
| AIM AIM ImmunoTech Inc. Common Stock | $7.51M | — | $0.17 | ▲ 0.00% | $0.1605$2.79 |
| CELZ Creative Medical Technology Holdings Inc. Common Stock | $7.58M | — | $0.741 | ▼ 9.39% | $0.62$6.25 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Christian Vasquez · May 31, 2026 · Tax Withholding82 @ $3.93
- Eric Sievers · May 31, 2026 · Tax Withholding134 @ $3.93
- Jay M. Short, PhD · May 31, 2026 · Tax Withholding259 @ $3.93
Institutional Ownership
March 31, 2026
- Total shares held
- 288.8K
- Total value held
- $46.2K
- Institutional holders
- 2
- Unknown277.6K
- Unknown11.1K
See the full, filterable feed with live charts on the MarketWall dashboard.